A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

The goal of this clinical trial is to evaluate the impact that ENV-101 has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF). Another goal of this study is to better understand the safety and tolerability of ENV-101 in this patient population.

Start Date15 Nov 2024

Sponsor / Collaborator

Endeavor BioMedicines, Inc

NCT05817240

/ CompletedPhase 1

A Phase 1, Single-Center, Fixed Sequence, Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects

The goal of this clinical trial is to learn about the potential effect of ENV-101 (taladegib) on the pharmacokinetics of nintedanib (an approved treatment for idiopathic pulmonary fibrosis) when the two compounds are dosed together in healthy subjects. Participants in this study will receive ENV-101 and/or nintedanib on various days throughout a 10-day period during which they will reside at the clinical trial site.

Start Date03 May 2023

Sponsor / Collaborator

Endeavor BioMedicines, Inc

NCT05199584

/ Active, not recruitingPhase 2

A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF) mutations in the Patched-1 (PTCH1) gene. Stage 1 of this study will enroll approximately 44 patients randomized between two dose levels. As appropriate, Stage 2 of the study will expand enrollment based on the results of Stage 1.

Start Date24 May 2022

Sponsor / Collaborator

Endeavor BioMedicines, Inc

100 Clinical Results associated with Taladegib

100 Translational Medicine associated with Taladegib

100 Patents (Medical) associated with Taladegib

Literatures (Medical) associated with Taladegib

01 Oct 2024·ARCHIV DER PHARMAZIE

A novel indole derivative, 2‐{3‐[1‐(benzylsulfonyl)piperidin‐4‐yl]‐2‐methyl‐1H‐indol‐1‐yl}‐1‐(pyrrolidin‐1‐yl)ethenone, suppresses hedgehog signaling and drug‐resistant tumor growth

Article

Author: Kim, Minkyoung ; Ko, Hyuk Wan ; Lee, Yoon Ji ; Jeon, Jiyeon ; Lee, Kyeong ; Lee, Hankyu ; Jung, Joo Hyun ; Nada, Hossam ; Lee, Hwayoung ; Bhattarai, Deepak

Abstract:

The Hedgehog (Hh) signaling pathway plays important roles in various physiological functions. Several malignancies, such as basal cell carcinoma (BCC) and medulloblastoma (MB), have been linked to the aberrant activation of Hh signaling. Although therapeutic drugs have been developed to inhibit Hh pathway‐dependent cancer growth, drug resistance remains a major obstacle in cancer treatment. Here, we show that the newly identified, 2‐{3‐[1‐(benzylsulfonyl)‐1,2,3,6‐tetrahydropyridin‐4‐yl]‐2‐methyl‐1H‐indol‐1‐yl}‐1‐(pyrrolidin‐1‐yl)ethenone analog (LKD1214) exhibits comparable potency to vismodegib in suppressing the Hh pathway activation. LKD1214 represses Smoothened (SMO) activity by blocking its ciliary translocation. Interestingly, we also identified that it has a distinctive binding interface with SMO compared with other SMO‐regulating chemicals. Notably, it maintains an inhibitory activity against the SmoD477H mutant, as observed in a patient with vismodegib‐resistant BCC. Furthermore, LKD1214 inhibits tumor growth in the mouse model of MB. Collectively, these findings suggest that LKD1214 has the therapeutic potential to overcome drug‐resistance in Hh‐dependent cancers.

01 Dec 2023·Cold Spring Harbor molecular case studies

Prostate cancer patient stratification by molecular signatures in the Veterans Precision Oncology Data Commons

Article

Author: La, Jennifer ; Fillmore, Nathanael R ; Hernandez, Kyle M ; Sung, Feng-Chi ; Metoki-Shlubsky, Noah ; Liu, Qiong ; Bihn, John R ; Grossman, Robert L ; Prokhorenkov, Andrew ; Brophy, Mary T ; Venkat, Aarti ; Paller, Channing J ; Elbers, Danne C ; Do, Nhan V

Veterans are at an increased risk for prostate cancer, a disease with extraordinary clinical and molecular heterogeneity, compared with the general population. However, little is known about the underlying molecular heterogeneity within the veteran population and its impact on patient management and treatment. Using clinical and targeted tumor sequencing data from the National Veterans Affairs health system, we conducted a retrospective cohort study on 45 patients with advanced prostate cancer in the Veterans Precision Oncology Data Commons (VPODC), most of whom were metastatic castration-resistant. We characterized the mutational burden in this cohort and conducted unsupervised clustering analysis to stratify patients by molecular alterations. Veterans with prostate cancer exhibited a mutational landscape broadly similar to prior studies, includingKMT2AandNOTCH1mutations associated with neuroendocrine prostate cancer phenotype, previously reported to be enriched in veterans. We also identified several potential novel mutations inPTEN,MSH6,VHL,SMO, andABL1. Hierarchical clustering analysis revealed two subgroups containing therapeutically targetable molecular features with novel mutational signatures distinct from those reported in the Catalogue of Somatic Mutations in Cancer database. The clustering approach presented in this study can potentially be used to clinically stratify patients based on their distinct mutational profiles and identify actionable somatic mutations for precision oncology.

24 Nov 2022·Journal of biomolecular structure & dynamics

Deep-learning based repurposing of FDA-approved drugs againstCandida albicansdihydrofolate reductase and molecular dynamics study

Article

Author: Joshi, Tanuja ; Chandra, Subhash ; Pundir, Hemlata

Candida albicans causes the fatal fungal bloodstream infection in humans called Candidiasis. Most of the Candida species are resistant to the antifungals used to treat them. Drug-resistant C. albicans poses very serious public health issues. To overcome this, the development of effective drugs with novel mechanism(s) of action is requisite. Drug repurposing is considered a viable alternative approach to overcome the above issue. In the present study, we have attempted to identify drugs that could target the essential enzyme, dihydrofolate reductase of C. albicans (CaDHFR) to find out potent and selective antifungal antifolates. FDA-approved-drug-library from the Selleck database containing 1930 drugs was screened against CaDHFR using deep-learning, molecular docking, X-score and similarity search methods. The screened compounds showing better binding with CaDHFR were subjected to molecular dynamics simulation (MDS). The results of post-MDS analysis like RMSD, RMSF, RG, SASA, the number of hydrogen bonds and PCA suggest that Paritaprevir, Lumacaftor and Rifampin can make good interaction with CaDHFR. Furthermore, analysis of binding free energy corroborated the stability of interactions as they had binding energy of -114.91 kJ mol^-1, -79.22 kJ mol^-1 and -78.52 kJ mol^-1 for Paritaprevir, Lumacaftor and Rifampin respectively as compared to the reference (-63.10 kJ mol^-1). From the results, we conclude that these drugs have great potential to inhibit CaDHFR and would add to the drug discovery against candidiasis, and hence these drugs for repurposing should be explored further.

News (Medical) associated with Taladegib

20 May 2025

·endeavorbiomedicines.com

Endeavor BioMedicines Presents New Clinical Findings From Post Hoc Analysis of Phase 2a Clinical Trial Evaluating ENV-101 in Patients with Idiopathic Pulmonary Fibrosis

Findings presented at the American Thoracic Society 2025 International Conference corroborate previous findings and provide important new clinical evidence supporting ENV-101 SAN DIEGO – May 20, 2025 – Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today presented a post hoc analysis from the completed Phase 2a clinical trial of its lead investigational therapy, ENV-101 (taladegib). Results demonstrated a significant reduction in pulmonary vessel volume, a significant increase in lung volume, and a trend towards reduced lung fibrosis for idiopathic pulmonary fibrosis (IPF) patients treated with ENV-101 for 12 weeks vs. placebo. The analysis utilized Qureight’s deep learning-based computed tomography (CT) analytics technologies and was presented in a poster presentation at the American Thoracic Society (ATS) 2025 International Conference. Lung volume, fibrotic tissue volume and pulmonary vessel volume are all volumetric lung measures that can change during IPF disease progression or in response to treatment. Each measure has been established as an independent predictor of mortality. Deep learning-based quantification of lung volume and pulmonary vascular changes may offer valuable insights that corroborate physiological improvement in lung function and measure treatment outcomes with a greater effect size than forced vital capacity (FVC), the current registrational endpoint in IPF. A new finding from this post hoc analysis demonstrated a significant reduction in pulmonary vessel volume for patients in the ENV-101 treatment arm versus placebo. A reduction in pulmonary vessel volume has been correlated with improved mortality and decreased disease burden. To date, ENV-101 is the only therapeutic that has demonstrated a reduction in pulmonary vessel volume in patients with IPF, providing further evidence that ENV-101 has the potential to reverse disease across multiple measures of IPF. “These findings provide additional evidence of clinical utility of ENV-101 in patients with IPF marking another step forward in our mission to restore hope and improve lives for those facing this otherwise devastating disease,” said Lisa Lancaster, M.D., Chief Medical Officer, Endeavor BioMedicines. “We are grateful to the Qureight team for partnering with us on this important analysis.” The post hoc analysis of the Phase 2a trial was conducted using novel deep learning-based CT analysis technologies developed by Qureight Ltd (Cambridge, UK). Qureight used three deep learning models developed to quantify lung volume (Lung8), pulmonary vessel volume (Vascul8), and fibrosis extent (Fibr8) on the baseline and follow-up CTs of ENV-101 treated and placebo patients (ENV-101 = 16; placebo = 18). Key Results from the Post Hoc Analysis Presented at ATS 2025 Significant increase in lung volume (Lung8) for patients in the ENV-101 treatment arm vs placebo (placebo: −113.07 mL vs ENV-101: 142.28 mL; p=0.014; effect size=0.87). Trend towards reduced fibrosis (Fibr8) for ENV-101 treated patients vs placebo (placebo: 1.32pp vs ENV-101: −1.32pp; p=0.063; effect size=−0.64). Significant reduction in normalized pulmonary vessel volume (Vascul8) for patients in the ENV-101 treatment arm vs placebo (placebo: 0.07pp vs ENV-101: -0.25pp; p=0.0007; effect size=-1.28). “We are excited to share significant findings from the post hoc analysis of the phase 2a clinical trial of ENV-101, highlighting our pulmonary vessel volume quantification model, Vascul8,” said Simon Walsh, M.D., Ph.D., Chief Scientific Officer, Qureight. “Using this model, we quantified a significant treatment effect from ENV-101, with a greater effect size than forced vital capacity. Qureight’s deep learning-based imaging biomarkers offer distinct advantages by capturing treatment signals from each prognostic compartment of the lung separately, optimizing for precision medicine.” About the ENV-101 Phase 2a Clinical Trial Data from the post hoc analysis independently validates and builds upon the previously reported results from the Phase 2a randomized, double-blind, multi-center, placebo-controlled clinical trial of ENV-101 (NCT04968574). In the trial, ENV-101 demonstrated significant improvements in lung function and total lung volume, while also showing a reduction in key measures of lung fibrosis versus placebo with a manageable safety profile. About the WHISTLE-PF Trial Endeavor continues to study ENV-101 and has initiated the Phase 2b WHISTLE-PF (Wound-remodeling Hedgehog-Inhibitor ILD Study Testing Lung Function Endpoints-PF) clinical trial, a global, randomized, placebo-controlled study evaluating the therapeutic potential of ENV-101 in individuals with IPF (NCT06422884). The WHISTLE-PF trial will evaluate the efficacy of a range of ENV-101 doses through 24 weeks of treatment, characterize the investigational compound’s safety, assess its effect on patient reported outcomes and its effects on lung capacity and lung fibrosis as measured by chest HRCT. About Idiopathic Pulmonary Fibrosis IPF is a chronic, progressive lung disease that affects more than 150,000 adults in the United States. Although the exact cause of IPF is unknown, various environmental factors can deliver repeated injuries to lung cells that trigger abnormal wound-healing processes and life-threatening lung scarring. IPF is a chronic disease with limited treatment options and a very poor prognosis: the average life expectancy is only three to five years after diagnosis. About ENV-101 Endeavor BioMedicines’ investigational medicine ENV-101 (taladegib) is a Hedgehog signaling pathway inhibitor. By binding to and inhibiting a key receptor in the Hedgehog pathway, ENV-101 stops the abnormal accumulation of the myofibroblasts that cause fibrosis. This may resolve the excessive wound-healing process seen in pulmonary fibrosis, improving lung volume and function. About Endeavor BioMedicines Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor’s lead candidate, ENV-101 (taladegib), is an inhibitor of the Hedgehog signaling pathway in development for fibrotic lung diseases, including idiopathic pulmonary fibrosis (IPF). The company’s second candidate, ENV-501, is a HER3 antibody-drug conjugate (ADC) in development for the treatment of HER3-positive solid tumors. More information is available at www.endeavorbiomedicines.com and on LinkedIn or X. Audra Friis Sam Brown, Inc. 917-519-9577 audrafriis@sambrown.com

Phase 2Clinical Result

20 Nov 2024

·www.businesswire.com

First Patient Dosed in Endeavor BioMedicines’ Phase 2b WHISTLE-PF Trial Evaluating ENV-101 for the Treatment of Idiopathic Pulmonary Fibrosis

SAN DIEGO--( BUSINESS WIRE )--Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced that the first patient has been dosed in the Phase 2b WHISTLE-PF trial evaluating the safety and efficacy of ENV-101 (taladegib), the company’s lead investigational medicine, in individuals with idiopathic pulmonary fibrosis (IPF). ENV-101 is a novel Hedgehog signaling pathway inhibitor that demonstrated potential in a Phase 2a trial to be the first disease-modifying treatment for IPF. “ Initiating the WHISTLE-PF trial is an important milestone for our company as we continue to develop ENV-101 for the treatment of IPF, a relentless disease that has a worse prognosis than most cancers," said John Hood, Ph.D., Co-founder, CEO and Chairman, Endeavor BioMedicines. “ Following the positive results from our Phase 2a trial of ENV-101, Endeavor BioMedicines is now intensely focused on efficiently advancing the WHISTLE-PF trial to get this potentially transformative drug to patients as quickly as possible.” IPF is a chronic, progressive lung disease with limited treatment options that affects approximately 150,000 adults in the United States. Although the exact cause of IPF is unknown, various environmental factors can deliver repeated injuries to lung cells that trigger abnormal wound-healing processes and life-threatening lung scarring. Current standard-of-care therapies do not address the underlying cause of IPF. They slow the decline of lung function, but do not stop or reverse it, and they have tolerability issues that limit their long-term use in most patients. ENV-101 is designed to block a cellular wound-healing pathway known as Hedgehog (Hh) that is abnormally activated in fibrotic lung diseases such as IPF and drives the continuous pathophysiologic buildup of scar tissue in the lungs. Results from the randomized, double-blind, placebo-controlled Phase 2a trial of ENV-101 showed that patients who received the investigational therapy experienced statistically significant improvements in lung function and total lung capacity, and reversal of multiple key quantitative measures of lung fibrosis through 12 weeks of treatment. There were no treatment-related serious adverse events, treatment-related grade 3 or 4 adverse events, or clinically meaningful safety findings on laboratory analyses, vital signs, electrocardiograms, or physical examination reported for ENV-101-treated patients. The Phase 2b WHISTLE-PF ( W ound-remodeling H edgehog-Inhibitor I LD S tudy T esting L ung F unction E ndpoints- PF ) clinical trial is a global, randomized, placebo-controlled study evaluating the therapeutic potential of ENV-101 in individuals with IPF ( NCT06422884 ). Endeavor BioMedicines intends to conduct the trial in 14 countries globally, including Australia, where the first patient was dosed. The WHISTLE-PF trial will evaluate the efficacy of a range of ENV-101 doses through 24 weeks of treatment, characterize the investigational compound’s safety, assess its effect on patient reported outcomes and its effects on lung capacity and lung fibrosis as measured by chest high-resolution computed tomography (HRCT). About Endeavor BioMedicines Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor’s lead candidate, ENV-101 (taladegib), is an inhibitor of the Hedgehog signaling pathway in development for fibrotic lung diseases, including idiopathic pulmonary fibrosis (IPF). The company’s second candidate, ENV-501, is a HER3 antibody-drug conjugate (ADC) in development for the treatment of HER3-positive solid tumors. More information is available at www.endeavorbiomedicines.com and on LinkedIn or X .

Phase 2Clinical ResultADC

12 Sep 2024

·endeavorbiomedicines.com

Endeavor BioMedicines Appoints Bill Bradford, M.D., Ph.D., to Board of Directors

SAN DIEGO – September 12, 2024 – Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today announced the appointment of Williamson “Bill” Bradford, M.D., Ph.D., to the company’s board of directors. Dr. Bradford brings over two decades of industry experience to the board, including executive leadership and clinical development expertise in idiopathic pulmonary fibrosis (IPF). “As we advance the clinical program for ENV-101, our lead investigational candidate in idiopathic pulmonary fibrosis, Dr. Bradford’s extensive knowledge and background in fibrotic lung disease – from the clinic to regulatory approval – will be an invaluable resource to our team,” said John Hood, Ph.D., Co-Founder, CEO and Chairman, Endeavor. “He is widely recognized for his executive and scientific leadership and we are honored to welcome him to our Board of Directors.” Dr. Bradford has more than 25 years of experience in the biopharmaceutical industry in executive leadership, product development, medical affairs, and board director roles. He is the Principal at Teton Bioscience and has provided drug development and strategic advisory services since 2015. He co-founded Indalo Therapeutics, a clinical-stage fibrosis company, served as a Board Director, and was Chief Medical Officer until 2020. Dr. Bradford also served as Senior Vice President, Clinical Development at InterMune, Inc. (acquired by Roche), where he led the successful development of Esbriet® (pirfenidone), an FDA-approved medication for the treatment of IPF and advanced a portfolio of therapeutics in the clinic across a range of therapeutic areas. Earlier in his career, Dr. Bradford held product development positions at Genentech (member of the Roche Group) and IntraBiotics Pharmaceuticals and was an infectious disease specialist and researcher at the University of California, San Francisco. “There is significant need to transform the current standard of care and improve quality of life for patients with idiopathic pulmonary fibrosis, and I believe Endeavor BioMedicines’ ENV-101 has the potential to change the trajectory of this life-threatening disease,” said Dr. Bradford. “I look forward to helping the Endeavor team accelerate the development of ENV-101 to bring this exciting new treatment option to patients suffering from fibrotic lung disease.” About Endeavor BioMedicines Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor’s lead candidate, ENV-101 (taladegib), is an inhibitor of the Hedgehog signaling pathway in clinical development for fibrotic lung diseases, including idiopathic pulmonary fibrosis (IPF). The company’s second candidate, ENV-501, is a HER3 antibody-drug conjugate (ADC) for the treatment of HER3-positive solid tumors. More information is available www.endeavorbiomedicines.com and on LinkedIn or X. Audra Friis Sam Brown Inc. 917-519-9577 audrafriis@sambrown.com

Executive Change

100 Deals associated with Taladegib

External Link

KEGG	Wiki	ATC	Drug Bank
D10671	-	-	DB12550

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Progressive fibrotic interstitial lung disease	Phase 2	United States	Endeavor BioMedicines, Inc	15 Nov 2024
Progressive fibrotic interstitial lung disease	Phase 2	Argentina	Endeavor BioMedicines, Inc	15 Nov 2024
Progressive fibrotic interstitial lung disease	Phase 2	Australia	Endeavor BioMedicines, Inc	15 Nov 2024
Progressive fibrotic interstitial lung disease	Phase 2	Austria	Endeavor BioMedicines, Inc	15 Nov 2024
Progressive fibrotic interstitial lung disease	Phase 2	Belgium	Endeavor BioMedicines, Inc	15 Nov 2024
Progressive fibrotic interstitial lung disease	Phase 2	Canada	Endeavor BioMedicines, Inc	15 Nov 2024
Progressive fibrotic interstitial lung disease	Phase 2	France	Endeavor BioMedicines, Inc	15 Nov 2024
Progressive fibrotic interstitial lung disease	Phase 2	Germany	Endeavor BioMedicines, Inc	15 Nov 2024
Progressive fibrotic interstitial lung disease	Phase 2	Ireland	Endeavor BioMedicines, Inc	15 Nov 2024
Progressive fibrotic interstitial lung disease	Phase 2	Italy	Endeavor BioMedicines, Inc	15 Nov 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04968574 (Company_Website) Manual	Phase 2	Idiopathic Pulmonary Fibrosis	-	ENV-101 (taladegib)	ondgkdurme(mvmwkfrves) = tlqwdhleao fchrcsbigk (ujimewbhye ) View more	Positive	20 May 2025
				Placebo	ondgkdurme(mvmwkfrves) = hdewuwtlgf fchrcsbigk (ujimewbhye ) View more
NCT04968574 (ENV-IPF-101, ATS2025)	Phase 2	Idiopathic Pulmonary Fibrosis lung volume \| vessel volume \| fibrosis extent ... View more	34	ENV-101 200 mg	fzmpsvsjoc(cxvmstgdqj) = dvdnhrojnn ssobmncwnt (lmiapmncaa ) View more	Positive	16 May 2025
				Placebo	fzmpsvsjoc(cxvmstgdqj) = nfvzqnrwsk ssobmncwnt (lmiapmncaa ) View more
NCT04968574 (ENV-IPF-101, ATS2024) Manual	Phase 2	Idiopathic Pulmonary Fibrosis	41	ENV-101	gbqqaqjnup(eemzadaajt) = The most common ENV-101-related adverse events were dysgeusia (alterations in taste; 57%), alopecia (52%) and muscle spasms (43%), which were all mild to moderate in severity. anybovebxe (bhncdobicw ) View more	Positive	19 May 2024
ENV-101 (EADV2023)	Phase 2	Basal Cell Carcinoma PTCH1 Loss of Function mutations	44	Taladegib 200 mg	wdkmidqkzo(rymkrgkubb) = Patient reported alopecia during the study tpthrhhdlq (medmekaqau ) View more	Positive	11 Oct 2023
				Vismodegib
NCT02784795 (I6F-MC-JJCD, Pubmed \| Invest New Drugs)	Phase 1	Metastatic Solid Tumor	63	Crenigacestat + Taladegib	nxjypnaqic(nzscvdzzwb) = ppuopxzbof owlkiqwabc (icskwysjim )	Negative	08 Mar 2021
				Crenigacestat + LY3023414	nxjypnaqic(nzscvdzzwb) = ijmukjyior owlkiqwabc (icskwysjim ) View more
NCT01919398 (CTgov)	Phase 1	Advanced Malignant Solid Neoplasm \| Advanced cancer	19	LY2940680 (Cohort 1: 100 mg LY2940680)	vsgrdluixs = nqhtoneirl balnryvkfj (hvulxqqfju, iffldjgxom - oamsqgeuvn) View more	-	11 Sep 2019
				LY2940680 (Cohort 2: 200 mg LY2940680)	vsgrdluixs = rtckcdtrrj balnryvkfj (hvulxqqfju, fnidefifji - situcgdafu) View more
NCT01746745 (CTgov)	Phase 1	-	6	[^14C]-LY2940680	ttcougugqe(nrtvssiirj) = ijayokbahi qplfrhhkcl (vyqnrsnkzb, 2.81) View more	-	22 Jul 2019
NCT01919398 (Pubmed \| Invest New Drugs) Manual	Phase 1	HR-positive/HER2-low Solid Tumors	19	taladegib	mcjbvuoxmg(bzhtccebin) = No dose-limiting toxicities (DLTs) were observed at doses of 100 mg or 200 mg; 3 of the 9 patients evaluable for DLTs at the 400 mg dose level experienced DLTs (thrombocytopenia: 1; decreased appetite: 2) dvhxzfopny (lkicbabioa ) View more	Positive	01 Aug 2018
NCT01226485 (Pubmed \| Clin Cancer Res) Manual	Phase 1	Basal Cell Carcinoma \| Advanced cancer	84	LY2940680	fltnyvdxfb(yxbflrjakf) = bwhmtszfyf kdupubkwax (tcdbkeuakk ) View more	Positive	01 May 2018

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis